Veno-occlusive disease after high-dose busulfan–melphalan in neuroblastoma

Tal Schechter*, Evelio Perez-Albuerne, Tiffany F. Lin, Meredith S. Irwin, Mohammed Essa, Ami V. Desai, Haydar Frangoul, Gregory Yanik, L. Lee Dupuis, David Jacobsohn, Morris Kletzel, Mark Ranalli, Sandeep Soni, Alix E. Seif, Stephan Grupp, Christopher C. Dvorak

*Corresponding author for this work

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Survival for high-risk neuroblastoma patients is still suboptimal. Although stem cell transplantation (SCT) is used, there is no consensus as to which conditioning regimen has the greatest efficacy and fewest toxicities. We assessed the incidence of and risk for hepatic veno-occlusive disease (VOD) for neuroblastoma patients who underwent autologous SCT with busulfan and melphalan (BuMel) at eight centers following Children’s Oncology Group (COG)-based induction chemotherapy. Data regarding the patients, SCT characteristics, busulfan steady-state concentrations, incidence of VOD, and survival were evaluated. VOD was defined using the modified Seattle criteria. Possible factors associated with VOD (age, busulfan-pharmacokinetic parameters, history of hepatic dysfunction, and day of neutrophil engraftment) were evaluated. Seventy five patients were included and 23 children (31%) developed VOD at a median of 19 days after SCT (range 14–27 days). VOD was the cause of death in 4 patients (5%). In a multivariable analysis, young age (OR 1.7 (95% CI: 1.16–2.56; p = 0.012)) and early day of neutrophil engraftment (OR 1.4 (95% CI: 1.08–2.14; p = 0.041) were associated with the development of VOD. Initial or cumulative busulfan steady-state concentration were not associated with VOD. We found that despite the use of intravenous busulfan with adjusted serum levels, the incidence of VOD remains high in pediatric neuroblastoma patients.

Original languageEnglish (US)
Pages (from-to)531-537
Number of pages7
JournalBone Marrow Transplantation
Volume55
Issue number3
DOIs
StatePublished - Mar 1 2020

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Veno-occlusive disease after high-dose busulfan–melphalan in neuroblastoma'. Together they form a unique fingerprint.

  • Cite this

    Schechter, T., Perez-Albuerne, E., Lin, T. F., Irwin, M. S., Essa, M., Desai, A. V., Frangoul, H., Yanik, G., Dupuis, L. L., Jacobsohn, D., Kletzel, M., Ranalli, M., Soni, S., Seif, A. E., Grupp, S., & Dvorak, C. C. (2020). Veno-occlusive disease after high-dose busulfan–melphalan in neuroblastoma. Bone Marrow Transplantation, 55(3), 531-537. https://doi.org/10.1038/s41409-018-0298-y